Business

Jenner & Block Settles $8 Million Fee Dispute With Ex-Client Government of Sierra Leone

Jenner & Block Settles $8 Million Fee Dispute With Ex-Client Government of Sierra Leone

Reporting, and expert analysis of legal technology with a focus onwhat legal departments, law firms, and tech companies need to know

The Am Law 100 is the definitive ranking of the 100 largest law firms in the United States.

Dynamically explore and compare data on law firms, companies, individual lawyers, and industry trends.

Real-time alerts on new state and federal litigation, plus unlimited complaint access, expert case summaries and AI-enhanced trend detection.

"Upon finalization of the settlement ... the Parties shall advise the Court as to the status of the settlement," counsel for Jenner & Block and the Republic of Sierra Leone wrote in a motion seeking a temporary pause in their court proceedings pending final resolution of their $8 million attorney-client fees dispute in the U.S. District Court for the District of Columbia.

Jenner & Block’s breach-of-contract lawsuit against the government of Sierra Leone is winding down in U.S. federal court after the parties agreed to settle claims alleging the West African nation failed to pay Jenner $8 million in outstanding attorney-client legal fees.

Is one article a month not enough? Subscribe today to unlock premium access to all the in-depth analysis and breaking news on critical legal issues from Law.com.

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Plaintiff Sysco Hampton Roads Inc. seeks injunctive relief and damages from its former employee Cole Winchester and direct competitor Performance Food Group in a complaint alleging the defendants conspired to steal Sysco's proprietary information in violation of the Defend Trade Secrets Act.

Pfizer alleges Novo Nordisk is attempting to "catch and kill" Metsera, a company Pfizer was in the process of acquiring, in an effort to stanch potential competition for Novo Nordisk's own obesity treatments, Ozempic and Wegovy.